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Abstract
Background:  Parkinson's disease (PD) is the most prevalent incurable neurodegenerative
movement disorder. Mutations in LRRK2 are associated with both autosomal dominant familial and
sporadic forms of PD. LRRK2 encodes a large putative serine/threonine kinase with GTPase activity.
Increased LRRK2 kinase activity plays a critical role in pathogenic LRRK2 mutant-induced
neurodegeneration in vitro. Little is known about the physiological function of LRRK2.
Results: We have recently identified a Drosophila line with a P-element insertion in an ortholog
gene of human LRRK2 (dLRRK). The insertion results in a truncated Drosophila LRRK variant with
N-terminal 1290 amino acids but lacking C-terminal kinase domain. The homozygous mutant fly
develops normally with normal life span as well as unchanged number and pattern of dopaminergic
neurons. However, dLRRK mutant flies were selectively sensitive to hydrogen peroxide induced
stress but not to paraquat, rotenone and β-mercaptoethanol induced stresses.
Conclusion: Our results indicate that inactivation of dLRRK kinase activity is not essential for fly
development and suggest that inhibition of LRRK activity may serve as a potential treatment of PD.
However, dLRRK kinase activity likely plays a role in protecting against oxidative stress.
Background
Parkinson's disease (PD) is a common and currently
incurable neurodegenerative movement disorder affecting
approximately 1–2% of the population over 65 years of
age. Clinically, it is characterized by age-dependent resting
tremor, muscular rigidity, and akinesia. Neuropathologi-
cally, selective loss of dopaminergic (DA) neurons in the
substantia nigra compacta region and Lewy body forma-
tion in the remaining neurons are two hallmarks of PD
patient brains [1].
The molecular mechanism of PD-specific neuropatholog-
ical changes and parkinsonism motor deficits are largely
unknown. Nevertheless, significant progress on molecular
genetics of PD has been made during the last several years
by studying familial PD cases. Mutations in at least 7
genes have been implicated in various forms of familial
PD cases. These genes include α-synuclein, uchL1, LRRK2,
parkin, PINK1, DJ-1, and ATP13A2 [2-10].
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LRRK2 was recently identified as a novel gene responsible
for an autosomal dominant form of PD, suggesting a toxic
gain of function of LRRK2 in affected cases [3,5]. So far, at
least 20 LRRK2 mutations have been identified from PD
patients, accounting for ~7% familial form of PD cases
and for a significant portion of sporadic PD cases [11,12].
Unlike other PD-associated genes, which normally are
correlated with early-onset or pathologically atypical
forms of PD, LRRK2 is associated with late-onset and clin-
ically idiopathic PD [3,5,12]. Thus, dysfunction of LRRK2
may impair a common pathway involving in pathogene-
sis of both familial and sporadic PD cases.
LRRK2 is a large protein (2527 amino acids) consisting of
several independent domains, including a leucine-rich
repeat domain, a Roc GTPase domain followed by its
associated C terminal of Roc (Rac) domain, a protein
kinase domain of the MAPKKK family, and a C-terminal
WD40 domain [13,14], suggesting a complexity of its cel-
lular function and regulation. Recent studies suggest that
LRRK2 can self-phosphorylate in vitro. Moreover, the
kinase activity of LRRK2 seems to be tightly regulated by
its GTPase activity [15]. PD related mutations results in
increased kinase activity of LRRK2 [16,17]. Thus, inactiva-
tion of LRRK2 kinase activity constitutes a potential strat-
egy for PD treatment. A critical point for this treatment
strategy is whether inhibition of LRRK2 physiological
activity will affect the normal development process or
induce severe pathological side effects.
In the present study, we investigated roles of LRRK2 in
development and neuronal survival using Drosophila as a
model system. Our results suggest that LRRK2 kinase
activity is not required for development, survival of DA
neurons, and protection of PD-related stress of Drosophila.
Results
Identification of Drosophila Line with LRRK2 Deletion
Sequence analysis revealed a single Drosophila ortholog
(CG5483) of human LRRK1  (hLRRK1) and LRRK2
(hLRRK2) [designated as Drosophila LRRK (dLRRK)].
dLRRK shares 24% identity and 38% similarity at the
amino acid (aa) level to hLRRK2. The kinase domain is
31% identical and 52% similar between dLRRK and
hLRRK2. The predicted critical amino acids for function of
LRRK2, including proton acceptor (D1994), ATP binding
site (K1906), and 9 of total 18 identified pathogenic
mutant amino acids, are highly conserved [see Additional
file 1] [12]. These results suggest that CG5483 is a Dro-
sophila ortholog of both hLRRK1 and hLRRK2.
We identified a fly line (e03680) with piggyBac element
insertion in the intron between exon 5 and exon 6 of
dLRRK gene [18] (Fig. 1). RT-PCR detects a mutant dLRRK
transcript with deletion of exon 6 (Fig 1a, b, c). Primer
extension analysis revealed the mutant dLRRK transcript
encoding N-terminal 1289aa, RYCNECA encoded by the
intron between exon 5 and exon 6, followed by an in-
frame stop codon. The transcript returns to exon 7 and the
whole C-terminal sequence after exon 7. Therefore, the
mutant fly harbors a truncated protein consisting of the
N-terminal ankyrin repeat (ANK), leucine-rich repeat
(LRR) and Rac domains. Thus, the resulted mutant fly car-
ries a kinase-null dLRRK (Fig. 1d).
Drosophila lacking dLRRK kinase activity are viable with 
normal development
Recent studies suggest that increased kinase activity plays
critical roles in neuronal death induced by pathogenic
LRRK2 mutants [17]. We therefore determined the roles of
the dLRRK kinase activity in fly development and DA neu-
ron survival. Homozygous dLRRK mutant files were gen-
erated. These mutant flies were viable, fertile and
developed with no obvious preadult or afteradult external
abnormality (not shown). They showed similar life span
to their wildtype counterparts (Fig 2a). Whole-mount
brain immunostaining with an anti-Drosophila  tyrosine
hydroxylase antibody revealed no detectable change of
number and distribution of DA neurons in flies at age 20
days in comparison with wildtype control flies (Fig 3).
The results suggest that inactivation of dLRRK kinase has
little affect on development, life span, and survival of DA
neurons in fly.
dLRRK mutant flies are selectively sensitive to hydrogen 
peroxide
Oxidative stress is implicated in PD pathogenesis [19,20].
We next determined the effects of oxidative stress on
dLRRK mutant flies. dLRRK mutant flies showed little dif-
ference in survival from their wiltype counterparts after
exposure to oxidants rotenone (250 μM), paraquat (5
mM), and unfolded protein inducer β-mercaptoethanol
(β-ME, 2 mM) (Fig. 2b, c, d) [21]. Paraquat and rotenone,
mitochondrial complex I inhibitors, induce PD-like selec-
tive degeneration of DA neurons [22,23]. In contrast,
hydrogen peroxide (H2O2) treatment (1%) resulted in
increased death of dLRRK mutant flies comparing to their
wildtype counterpart (Fig. 2e). Unlike paraquat and
rotenone, H2O2 induces a more general oxidative stress
that is not selective for the DA neuron. The results suggest
that loss of LRRK function unlikely trigger the selective
sensitivity to DA neuron preferential or mitochondria ini-
tiated oxidative stress in fly. However, dLRRK mutant flies
are more sensitive to general and overall oxidative stress
than wildtype flies.
Discussion
LRRK2 mutations are linked to a significant number of
both familial and sporadic PD cases, little is known about
the biological functions and PD-related pathogenic mech-Molecular Neurodegeneration 2008, 3:3 http://www.molecularneurodegeneration.com/content/3/1/3
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Identification of Drosophila Line with LRRK2 Deletion Figure 1
Identification of Drosophila Line with LRRK2 Deletion. Schematic representation of the piggyBac element insertion site 
of Drosophila line e03680. (a). The dLRRK gene has 11 exons (arrow boxes) and 10 introns (black line between exons). The 
piggyBac insertion site is indicted by a filled block arrow. 4 pairs of primers used for RT-PCR analysis of dLRRK transcripts are 
also indicated. These include 1351 and 1561; 3374 and 3604; 3776 and 3996; 5091 and 4237. Positions and directions of differ-
ent primers are marked with vertical black lines and horizontal arrows. (b) dLRRK transcripts in various fly lines are detected 
with RT-PCR. C, negative control; WT, +/+ fly; HE, e03680/+ fly; HO, e03680/e03680 fly. (c). The flanking sequence of piggy-
Bac insertion was shown. (d). Schematic representation of wt dLRRK protein and mutant dLRRK protein in fly line e03680. 
ANK, N-terminal ankyrin repeat domain; LRR, leucine-rich repeat domain; Rac, C terminal of Roc GTPase domain; S_TKc, Ser-
ine/Threonine protein kinases domain.Molecular Neurodegeneration 2008, 3:3 http://www.molecularneurodegeneration.com/content/3/1/3
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anism of this protein. We have shown in this study that
inactivation of dLRRK kinase activity has no effect on the
development and DA neuronal survival of Drosophila.
Recent studies using transfected cells suggest that PD-asso-
ciated LRRK2 mutants have increased kianse activity.
Moreover, the increased kinase activity is correlated with
dLRRK mutant flies are selectively sensitive to hydrogen peroxide Figure 2
dLRRK mutant flies are selectively sensitive to hydrogen peroxide. Wild type flies and dLRRK mutant flies have similar 
life span (a). Wild type flies and dLRRK mutant flies were treated with 250 μM rotenone (b), 5 mM paraquat (c), 2 mM β-ME (d) 
and 1% H2O2 (e). Note: dLRRK mutant flies have similar sensitivity to normal flies towards treatments of PD-associated stress 
inducer rotenone and paraquat, as well as misfolded protein stressor β-ME. dLRRK mutant flies show increased sensitivity to 
general oxidative stress inducer H2O2.Molecular Neurodegeneration 2008, 3:3 http://www.molecularneurodegeneration.com/content/3/1/3
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increased susceptibility to cell death [24]. This observa-
tion is consistent with finding of association of human
LRRK2 mutations with autosomal dominant form of PD.
The PD-associated LRRK2 mutant proteins likely contrib-
ute to PD pathogenesis via gain of deleterious functions.
If LRRK2 functions are conserved between Drosophila and
human, our observation suggests a potential strategy for
PD treatment via developing LRRK2 kinase inhibitors
Another interesting finding of this study is that loss of
LRRK2 kinase activity does not change sensitivity of Dro-
sophila  to PD related stress reagents. Rotenone and
paraquat are shown to induce parkinsonism in multiple
animal models and in human. Despite the precise mech-
anism remains unknown, the two chemicals inhibit mito-
chondrial complex I activity [25,26]. On the other hand,
inactivation of dLRRK kinase activity results in increased
susceptibility of Drosophila  to a general oxidant H2O2.
Together, these results suggest that dLRRK likely plays a
role in protecting against non-mitochondrial oxidative
stress. Nevertheless, the implication of this finding in PD
pathogenesis needs to be further verified in mammalian
models, given that there are two LRRK homologs in mam-
mals.
Drosophila lacking dLRRK kinase activity has normal development of DA neuron Figure 3
Drosophila lacking dLRRK kinase activity has normal development of DA neuron. Brain dissected from wild-type 
flies (a), e03680/+ flies (b) and e03680/e03680 flies (c) aged 20 days were immunostained with anti-Drosophila TH antibody fol-
lowed by an Alexa Fluor 594-labeled secondary antibody to indentify DA neurons. Representative pictures shown were col-
lected by confocal microscopy. Dopaminergic neurons in six brain regions, including PAL, PPM1/2, PPM3, PPL1, PPL2, and 
VUM, were quantified and no significant difference was found among different fly lines (d). Localization of Drosophila DA neu-
rons is illustrated in e.Molecular Neurodegeneration 2008, 3:3 http://www.molecularneurodegeneration.com/content/3/1/3
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A recent study suggests that inactivation of dLRRK results
in severely impaired locomotive activity and degeneration
of dopaminergic neurons [27] that are not found in this
study. The discrepancy between the two studies remains
to be resolved by further investigation.
Conclusion
In summary, we have found that dLRRK kinase activity is
not required for normal development and growth. The
results will facilitate our understanding of pathophysio-
logical function of human LRRK2.
Methods
Drosophila stocks and reagents
e03680 flies were obtained from the Exelixis collection at
Harvard Medical School.  Drosophila were maintained on
standard cornmeal-molasses-agar medium at 25°C.
Anti-Drosophila TH antibody (1:500) was generously pro-
vided by Dr. Neckameyer (Department of Pharmacologi-
cal and Physiological Science, Saint Louis University
School of Medicine, St. Louis, Missouri 63104), Alexa
Fluor 594 goat anti-rabbit IgG was from Invitrogen (San
Diego, CA). Hydrogen peroxide, paraquat, rotenone and
β-ME were purchased from Sigma.
Checking and Identification of piggyBac Insertion sites
Genomic DNA was purified from wild type, e03680/+ or
e03680/e03680 flies. According to the piggyBac element
insertion site information from Exelixis collection at Har-
vard Medical School. Several pairs of primers were
designed around insertion site and PCR was performed to
check the band size, including 1351–1561, 3374–3604,
3776–3996, and 5091–5237. For sequencing flanking
sequence, we used primers 3776-100R and 473L-3996 to
amplify 5' and 3' flanking DNA, then sent DNA fragment
for sequencing. The sequences of primers are 1351:
GTAAGGGTTCCCTGGATGGT; 1561: GGCCTATTGGT-
GCAGGTAGA; 3374: TAAGTTGCCGGACCCTACAC;
3604: 111TCATCTGTTCGGTGACCAAG; 3776: AGAT-
CAACCCCTTTGCTCCT; 3995: AGCTTAACCGTGCTTC-
CTGA; 5091: AGGTGCTTTTGGGTTCGTTT; 5273:
ATCCCGACCAAGGGTACAAT; 100R: TCCTAAAT-
GCACAGCGACGG; 473L: ACCTCGATATACAGACCG.
Primers used for 5' RACE experiment including: RACE-1:
GACTCGAGTCGACGAATTCAATTTTTTTTTTTTTTTTT;
RACE-2: GACTCGAGTCGACGAATTCAA; 4042R:
CGGACGGGAAATAAGTCATC; 3954R: CGAAGGCAG-
TAAGGAGGGTA
Whole mount immunostaining
Whole mount immunostaining of fly brains was done as
previous described [28]. Briefly, fly heads were fixed with
4% paraformaldehyde containing 0.2% Triton X-100
overnight and washed with PBT (PBS containing 0.2% Tri-
ton X-100) 3 times. Brains were dissected in blocking
buffer (PBS, 5% heat inactivated normal goat serum, 0.2%
Triton X-100), followed by blocking at room temperature
for 1 hour. Brains were immunostained with correspond-
ing primary antibodies at 4°C overnight followed by
respective secondary antibodies at room temperature for 3
hr. DA neurons were quantified using confocal images
and analyzed statistically using InStat 3 (GraphPad, San
Diego).
Lifespan
Approximately 500 flies per genotype were analyzed in
the lifespan study. The flies were transferred to new vials
every second day and the number of dead flies in each vial
was recorded. The experiment was continued until all flies
were dead. The percentage of flies alive at each time point
was quantified and graphed.
Compounds treatment
3–5 days old flies were used for all treatments. At least 100
flies were used for each treatment. Flies were first starved
for 3 hours and then transferred to vials with filter papers
soaked with toxic compound containing 5% sucrose. Flies
were transferred to new vials with fresh compound every
day, and the number of dead flies in each vial was
recorded. The experiment was continued until all flies
were dead. The percentage of flies alive at each time point
was quantified and graphed. Chemical compounds were
administered at the following doses: 250 μM rotenone, 5
mM paraquat and 2 mM β-ME.
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GTPase domain. Highlighted red indicates kinase domain. Highlighted 
blue indicates the conserved PD associated point mutation sites between 
human and Drosophila.
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